CSIMarket Company Name, Ticker, Industry, else..
 

Heron Therapeutics Inc   (NASDAQ: HRTX)

Heron Therapeutics Inc 's

Competitiveness



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 

HRTX Sales vs. its Competitors Q2 2026


Comparing the current results to its competitors, Heron Therapeutics Inc reported Revenue increase in the 2 quarter 2026 by 3.64 % year on year, while most of its competitors have experienced contraction in revenues by -14.67 %, achieved in the same quarter.

• List of HRTX Competitors





Revenue Growth Comparisons




Net Income Comparison

Heron Therapeutics Inc recorded a net loss, as well as most of its competitors.

<<  HRTX Stock Performance Comparisons


Heron Therapeutics Inc 's Comment on Competition and Industry Peers


The company operates in the biotechnology and pharmaceutical industries, which are highly competitive and include major and mid-sized companies with greater financial, technical, and operational resources. Competitors often have more experience in strategic partnerships, in-licensing technology, drug development, regulatory approvals, manufacturing, and marketing. The company faces competition from firms that may develop products potentially rendering its offerings obsolete or noncompetitive. The company has a co-promotion agreement with Crosslink Network, LLC.



  

Overall company Market Share Q2 2026
Overall company revenue, increased by 3.64 % faster than Heron Therapeutics Inc 's competitors within this division and its market share improved to approx. 16.92 %.
<<  More on HRTX Market Share.
 
*Market share is calculated based on total revenue.





Publicly Traded Peers of Heron Therapeutics Inc




Zymeworks Inc
Share Performance



+67.09%
One Year
Zymeworks Inc
Profile

Zymeworks Inc is a biotechnology company that operates on a licensing and collaboration business model. They primarily generate revenue through partnerships and collaborations with pharmaceutical and biotechnology companies, providing access to their proprietary drug development platform and expertise in protein engineering. This enables them to advance the development of novel bi-specific antibodies and therapeutic proteins for the treatment of various diseases and medical conditions.

More about Zymeworks Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 1,919.724 mill. $ 37.127 mill. $ -149.992 mill.


Phio Pharmaceuticals Corp
Share Performance



-52.29%
One Year
Phio Pharmaceuticals Corp
Profile

Phio Pharmaceuticals Corp's business model revolves around developing and commercializing innovative RNA-based therapeutics to treat various diseases and improve patient outcomes.

More about Phio Pharmaceuticals Corp's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 12.082 mill. $ - mill. $ -12.904 mill.


Oramed Pharmaceuticals Inc
Share Performance



+61.59%
This Year
Oramed Pharmaceuticals Inc
Profile

Oramed Pharmaceuticals Inc. is a biopharmaceutical company with a business model focused on developing innovative oral drug delivery solutions.

More about Oramed Pharmaceuticals Inc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 199.858 mill. $ - mill. $ 174.864 mill.


Nextcure Inc
Share Performance



-4.46%
Over The Past 5 Days
Nextcure Inc
Profile

NextCure Inc is a biopharmaceutical company that operates with a unique business model. They focus on discovering and developing novel immunomedicines to treat various forms of cancer and other immune-related diseases. With a focus on developing innovative therapies that target immune cells, NextCure aims to provide effective and personalized treatment options for patients in need.

More about Nextcure Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 39.770 mill. $ - mill. $ -42.748 mill.


Nuvalent Inc
Share Performance



+0.05%
Over The Past 5 Days
Nuvalent Inc
Profile

Nuvalent Inc's business model entails developing innovative pharmaceutical solutions utilizing its proprietary technology and expertise.

More about Nuvalent Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 9,751.979 mill. $ - mill. $ -450.074 mill.

26 more competitors available

Sign in to see all competitors

Sign In Create Free Account

Sources: Heron Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Heron Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.